GlassScriptPhysician profile
Keturah Bowe
NPI 1659909513
$1,927.83
in general payments reported to CMS, 2019-2025
20 companies · $573 in 2025
The $573 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.56 · 2023: $500 · 2024: $831 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.91 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $237.93 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Dynavax Technologies Corporation | $214.17 | 2024-2025 | Heplisav-B |
| Medtronic, INC. | $178.37 | 2023-2025 | Minimed 780g, Synchromedii |
| Abiomed | $177.91 | 2023-2024 | Impella |
| Pfizer INC. | $165.77 | 2023-2025 | |
| Novo Nordisk INC | $144.06 | 2024-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $117.94 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $73.75 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $48.97 | 2023-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $44.36 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.65 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.26 | 2022-2025 | Jardiance |
| Ethicon INC. | $28.62 | 2024 | Monarch Platform |
| Hologic Sales and Service, LLC | $20.11 | 2024 | Aptima |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.90 | 2025 | |
| Glaxosmithkline, LLC. | $16.76 | 2024 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.52 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $14.04 | 2025 | Xelstrym |
| Axsome Therapeutics, INC. | $13.83 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keturah Bowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.